Selank complete guide

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (IMG RAS), where it was first synthesized in 1989 as a stabilized analog of the endogenous immunopeptide tuftsin. It belongs to a small family of Russian-origin neuropeptides — alongside its sister compound Semax — that emerged from a research programme aimed at producing short, peptidergic regulators with neurotropic activity. The published corpus around Selank is dominated by anxiolytic-research, GABAergic-system modulation, BDNF expression, monoamine-metabolism, and immune-modulation literature.

This guide is a mechanism-focused deep-dive: where Selank came from, how the C-terminal PGP modification of tuftsin produces a stabilized heptapeptide, what the published GABAergic and neurotrophic research actually documents, and how it sits relative to the broader Russian neuropeptide research lineage. Everything is research-frame language. No protocol guidance. No clinical recommendations.

Quick reference — Selank identifiers

Property	Selank
Class	Synthetic heptapeptide tuftsin analog
Peptide sequence	TKPRPGP (Thr-Lys-Pro-Arg-Pro-Gly-Pro)
Molecular formula	C33H57N11O9
Molecular weight	751.88 g/mol (free peptide; reported values 751–776 g/mol depending on salt form)
CAS	129954-34-3
Origin	Synthetic analog of endogenous immunopeptide tuftsin (TKPR), modified at the C-terminal with a PGP extension for enzymatic stability
Plasma half-life	Extended versus tuftsin via PGP-stabilization (parent tuftsin is rapidly cleaved by aminopeptidases)
Vial strengths (TogoPeptide)	5 mg lyophilized; also part of the Cognitive Stack

Origin and structure — tuftsin-derived heptapeptide

The parent compound tuftsin is a tetrapeptide with the sequence Thr-Lys-Pro-Arg (TKPR). It was first isolated in 1970 by Najjar and colleagues from the Fc fragment of immunoglobulin G (IgG) heavy chain, where it sits as residues 289–292. Tuftsin was originally characterised as a phagocytosis-stimulating peptide — its endogenous role being to activate macrophages and neutrophils as part of the innate-immunity response. The tetrapeptide has measurable neurotropic activity, but is rapidly cleaved by aminopeptidases in plasma, limiting its experimental utility.

Selank was designed at the Institute of Molecular Genetics, Russian Academy of Sciences (IMG RAS), to address that pharmacokinetic limitation. The strategy was to extend the C-terminal of tuftsin with a Pro-Gly-Pro (PGP) tripeptide tag. The resulting heptapeptide TKPRPGP retains the tuftsin pharmacophore at the N-terminal but is markedly more resistant to enzymatic degradation. The PGP fragment itself is a known glioprotective tripeptide that contributes its own pharmacological footprint to the resulting molecule.

Selank emerged from the same Russian research lineage that produced its sister compound Semax — a heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4–7 with an analogous PGP-extension stabilization strategy. Both compounds reflect the same design philosophy: take a short endogenous regulator with known neurotropic properties, append a PGP tag for enzymatic stability, characterise the resulting heptapeptide as a research neuropeptide. Selank and Semax remain the two most-cited compounds from this Russian neuropeptide research programme.

Mechanism — multi-system neuropeptide

Selank’s research footprint spans GABAergic, monoaminergic, neurotrophic, enkephalinergic, and immune-modulation literature. The mechanism is not single-pathway; published research documents Selank acting on several converging systems simultaneously.

GABAergic system modulation

The dominant mechanism for Selank’s anxiolytic-research framing is its effect on the GABAergic system. Published research documents Selank-induced changes in GABA-A receptor subunit expression and functional response in research-animal brain regions including the hippocampus, frontal cortex and amygdala [3]. The mechanism appears to be transcriptional — Selank modulates expression of genes encoding GABA-A receptor subunits and GABA-related neurotransmission components — rather than direct allosteric binding at the benzodiazepine site of the receptor.

This transcriptional, indirect modulation is what makes Selank mechanistically distinct from classical benzodiazepine GABA-A allosteric modulators. Selank does not bind the benzodiazepine site, and the published research does not document the sedation, motor impairment or dependence-liability profile that defines the benzodiazepine pharmacological class.

BDNF and neurotrophic effects

A separate Selank research line documents upregulation of brain-derived neurotrophic factor (BDNF) expression in hippocampus and cortex in research-animal models [6]. Intranasal administration in published rodent designs produced measurable increases in hippocampal BDNF mRNA and protein, alongside changes in expression of other neurotrophic-system components. This research line places Selank adjacent to the broader BDNF-modulation neuropeptide literature, where its sister compound Semax has the larger published corpus.

Serotonergic and dopaminergic modulation

A secondary mechanism layer documented in the published Selank corpus is modulation of biogenic-amine metabolism — including serotonin (5-HT) turnover, dopamine pathways, and norepinephrine signaling in research-animal brain tissue [2]. Published work documents Selank-induced changes in serotonin metabolism in stress-paradigm research designs, providing a candidate mechanism that overlaps with classical anxiolytic-pharmacology research lines without involving benzodiazepine receptors.

Enkephalinase inhibition

Selank inhibits enkephalin-degrading enzymes (enkephalinases) in research models, prolonging the signaling lifetime of endogenous enkephalins. This mechanism overlaps with the broader endogenous-opioid neuropeptide research line and contributes to the published anxiolytic-research and analgesic-research framing of the Selank corpus.

Immune-modulation

Selank inherits the immunopeptide activity of its parent compound tuftsin. Published research documents Selank effects on phagocytosis activation, cytokine modulation, and interferon-system signaling in research-animal designs. This is the research line that connects Selank back to the original 1970s tuftsin discovery and that defines its position as a neuro-immunological peptide rather than a purely neurotropic compound.

Anxiolytic-research literature

The largest published Selank research line is anxiolytic. Rodent-model research using the standard anxiolytic-research test battery — elevated plus maze, open field, conflict tests, and Vogel-conflict paradigms — has consistently documented Selank-induced changes in stress-paradigm behavioural endpoints across multiple research groups [1]. The published research positions Selank as anxiolytic-active in these standard rodent paradigms.

It is important to note that the Selank clinical-research lineage developed within the Russian regulatory framework, which differs from the Western drug-approval pathway. The compound has been studied under that framework in research populations with anxiety-research endpoints [5]. This research is part of the published peer-reviewed corpus — but its regulatory framing is distinct from the FDA / EMA pathway and the published material referenced here is research literature, not therapeutic recommendation.

Cognitive and memory research

A smaller but distinct Selank research line documents effects on learning, memory consolidation and attention paradigms in research-animal models. Published research using Morris water-maze, passive-avoidance and conditioned-response designs has documented Selank-induced changes in memory-consolidation endpoints in research-animal designs [4].

Mechanistically, the cognitive-research line overlaps with the BDNF-upregulation work — published research suggests the cognitive-paradigm changes track Selank’s neurotrophic effects in hippocampus and cortex. This places Selank adjacent to (but mechanistically distinct from) its sister compound Semax, where the cognitive and BDNF-modulation research corpus is larger and more developed.

Selank vs Semax — sister neuropeptides

Selank and Semax are the two most-cited compounds from the Russian Institute of Molecular Genetics neuropeptide research programme. They share the design philosophy (short endogenous regulator + PGP-extension for stability) but derive from different parent peptides and have meaningfully different research profiles.

Aspect	Selank	Semax
Parent peptide	Tuftsin (TKPR — IgG Fc immunopeptide)	ACTH(4–7) (MEHFP — adrenocorticotropic hormone fragment)
Sequence	TKPRPGP	MEHFPGP
Primary mechanism	GABA-system modulation + multi-system anxiolytic	BDNF / NGF upregulation + cognitive-research line
Best-characterised research line	Anxiolytic, GABAergic, immune-modulation	Cognitive, neurotrophic, neuroprotective
Origin institute	Institute of Molecular Genetics, Russian Academy of Sciences (IMG RAS) — both compounds from the same Russian neuropeptide research programme.

Administration routes in research

Published Selank research has used both intranasal and parenteral administration routes. The intranasal route is the historical standard in the Russian research-protocol lineage and is the route most commonly referenced in the published Selank corpus — the heptapeptide crosses the nasal mucosa and reaches central nervous-system tissue without first-pass metabolism. Parenteral routes have also been used in published research designs, particularly in mechanism-of-action studies where dose-precision is the priority over route-realism.

The choice of route in research design has implications for the published mechanism endpoints — intranasal-administration research documents central-nervous-system effects (BDNF expression, GABA-receptor modulation, cognitive paradigms) while parenteral-administration research documents the broader systemic profile including immune-modulation and biogenic-amine metabolism endpoints.

Storage and handling

Selank ships as lyophilized powder. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window (typically 24+ months).
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent for research-grade peptide handling.
• Reconstituted state: refrigerate at 2–8°C. Use within ~28 days under refrigeration.
• Avoid freeze-thaw cycles after reconstitution — repeated freezing and thawing degrades peptide integrity.
• Light protection: store the reconstituted vial in an opaque or amber container, away from prolonged light exposure.

Each TogoPeptide Selank shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date, analysis date. See how to read a COA or reconstitution methodology for the methodology details.

Cross-research lines and pairings

• Cognitive Stack — Selank + Semax + DSIP: the curated three-compound research stack pairs Selank’s anxiolytic-research mechanism with Semax’s BDNF / cognitive corpus and DSIP’s sleep-architecture research line. The most common combined-peptide design in the cognitive neuropeptide research literature.
• Selank + Semax pairing: the two sister Russian-origin neuropeptides are commonly paired in research designs because the mechanisms are complementary — GABA-system / anxiolytic plus BDNF / cognitive — with both compounds sharing the same intranasal-administration research lineage.
• Vial strength: Selank ships at 5 mg per vial. Reconstitution math is documented in the reconstitution calculator.

Closing

Selank is a Russian-origin synthetic heptapeptide derived from the endogenous immunopeptide tuftsin, stabilized via a C-terminal PGP extension at the Institute of Molecular Genetics, Russian Academy of Sciences. The mechanism converges on GABAergic-system modulation, BDNF expression, monoamine-metabolism changes, enkephalinase inhibition and immune-modulation — producing a multi-system neuropeptide whose published anxiolytic-research and cognitive-research corpus is mechanistically distinct from classical benzodiazepine GABA-A allosteric modulators.

This guide documents what published peer-reviewed research has investigated. It is mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source Selank for laboratory research:

• Selank product page — full identifiers, 5 mg vial, per-batch COA
• Cognitive Stack — curated three-compound research stack (Selank + Semax + DSIP)
• Cognitive research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.